Diagnostic and prognostic biomarkers for tubulointerstitial fibrosis
- PMID: 37227074
- DOI: 10.1113/JP284289
Diagnostic and prognostic biomarkers for tubulointerstitial fibrosis
Abstract
Renal fibrosis is the final common pathophysiological pathway in chronic kidney disease (CKD) regardless of the underlying cause of kidney injury. Tubulointerstitial fibrosis (TIF) is considered to be the key pathological predictor of CKD progression. Currently, the gold-standard tool to identify TIF is kidney biopsy, an invasive method that carries risks. Non-invasive diagnostics rely on an estimation of glomerular filtration rate and albuminuria to assess kidney function, but these fail to diagnose early CKD accurately or to predict progressive decline in kidney function. In this review, we summarize the current and emerging molecular biomarkers that have been studied in various clinical settings and in animal models of kidney disease and that are correlated with the degree of TIF. We examine the potential of these biomarkers to diagnose TIF non-invasively and to predict disease progression. We also examine the potential of new technologies and non-invasive diagnostic approaches in assessing TIF. Limitations of current and potential biomarkers are discussed and knowledge gaps identified.
Keywords: biomarkers; chronic kidney disease; non-invasive diagnostics; renal fibrosis; tubulointerstitial fibrosis.
© 2023 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
Similar articles
-
Urinary exosomes derived circRNAs as biomarkers for chronic renal fibrosis.Ann Med. 2022 Dec;54(1):1966-1976. doi: 10.1080/07853890.2022.2098374. Ann Med. 2022. PMID: 35819256 Free PMC article.
-
Pathophysiology of unilateral ischemia-reperfusion injury: importance of renal counterbalance and implications for the AKI-CKD transition.Am J Physiol Renal Physiol. 2020 May 1;318(5):F1086-F1099. doi: 10.1152/ajprenal.00590.2019. Epub 2020 Mar 16. Am J Physiol Renal Physiol. 2020. PMID: 32174143 Free PMC article.
-
The role of tubulointerstitial markers in differential diagnosis and prognosis in patients with type 2 diabetes and biopsy proven diabetic kidney disease.Clin Chim Acta. 2023 Jul 1;547:117448. doi: 10.1016/j.cca.2023.117448. Epub 2023 Jun 17. Clin Chim Acta. 2023. PMID: 37331550
-
Renal fibrosis: Primacy of the proximal tubule.Matrix Biol. 2018 Aug;68-69:248-262. doi: 10.1016/j.matbio.2018.02.006. Epub 2018 Feb 6. Matrix Biol. 2018. PMID: 29425694 Free PMC article. Review.
-
Hypoxia and Renal Tubulointerstitial Fibrosis.Adv Exp Med Biol. 2019;1165:467-485. doi: 10.1007/978-981-13-8871-2_23. Adv Exp Med Biol. 2019. PMID: 31399980 Review.
Cited by
-
Urinary long non-coding RNA GAS5 as a noninvasive diagnostic biomarker for renal fibrosis.Ren Fail. 2025 Dec;47(1):2534493. doi: 10.1080/0886022X.2025.2534493. Epub 2025 Jul 20. Ren Fail. 2025. PMID: 40685500 Free PMC article.
-
Mechanism of Astragaloside IV in Treatment of Renal Tubulointerstitial Fibrosis.Chin J Integr Med. 2025 May;31(5):474-480. doi: 10.1007/s11655-024-3805-6. Epub 2024 Jun 8. Chin J Integr Med. 2025. PMID: 38850482 Review.
-
Emerging Biomarkers and Advanced Diagnostics in Chronic Kidney Disease: Early Detection Through Multi-Omics and AI.Diagnostics (Basel). 2025 May 13;15(10):1225. doi: 10.3390/diagnostics15101225. Diagnostics (Basel). 2025. PMID: 40428218 Free PMC article. Review.
-
Matrix metalloproteinase-10 promotes kidney fibrosis by transactivating β-catenin signaling.Cell Death Discov. 2025 May 17;11(1):241. doi: 10.1038/s41420-025-02521-w. Cell Death Discov. 2025. PMID: 40382334 Free PMC article.
-
Towards clinical translation of urinary vitronectin for non-invasive detection and monitoring of renal fibrosis in kidney transplant patients.J Transl Med. 2024 Nov 15;22(1):1030. doi: 10.1186/s12967-024-05777-5. J Transl Med. 2024. PMID: 39548536 Free PMC article.
References
-
- Aapro, M., Gascon, P., Patel, K., Rodgers, G. M., Fung, S., Arantes, L. H., Jr., & Wish, J. (2018). Erythropoiesis-stimulating agents in the management of anemia in chronic kidney disease or cancer: A historical perspective. Frontiers in Pharmacology, 9, 1498.
-
- Abe, H., Sakurai, A., Ono, H., Hayashi, S., Yoshimoto, S., Ochi, A., Ueda, S., Nishimura, K., Shibata, E., Tamaki, M., Kishi, F., Kishi, S., Murakami, T., Nagai, K., & Doi, T. (2018). Urinary exosomal mRNA of WT1 as diagnostic and prognostic biomarker for diabetic nephropathy. Journal of Medical Investigation, 65(3.4), 208-215.
-
- Afkarian, M., Zelnick, L. R., Ruzinski, J., Kestenbaum, B., Himmelfarb, J., de Boer, I. H., & Mehrotra, R. (2015). Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes. Journal of Diabetes and Its Complications, 29(8), 1024-1031.
-
- Annes, J. P., Munger, J. S., & Rifkin, D. B. (2003). Making sense of latent TGFbeta activation. Journal of Cell Science, 116(2), 217-224.
-
- Astor, B. C., Matsushita, K., Gansevoort, R. T., van der Velde, M., Woodward, M., Levey, A. S., Jong, P. E., Coresh, J., Chronic Kidney Disease Prognosis, C., Astor, B. C., Matsushita, K., Gansevoort, R. T., van der Velde, M., Woodward, M., Levey, A. S., de Jong, P. E., Coresh, J., El-Nahas, M., Eckardt, K. U., … Manley, T. (2011). Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International, 79(12), 1331-1340.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical